Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers

Elmekawy, H A; Belal, Fathalla; Abdelaziz, A E; Abdelkawy, Khaled; Ali, A A; Elbarbry, Fawzy

doi:10.1007/s00228-021-03130-z

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myalgia is the main interaction risk from statin interactions (Elmekawy et al, 2021, Sharaf et al, 2021. Patients should be informed about symptoms and signs for expected outcomes of these interactions.…”

Section: Resultsmentioning

confidence: 99%

Potential Cardiovascular Drug Interactions in Egypt: Incidence, Outcomes, Mechanism, and Management

Sobhy

Abdelmagged

Abdelaty

et al. 2021

Kafrelsheikh Veterinary Medical Journal

View full text Add to dashboard Cite

Background/aim: Cardiovascular diseases usually involve multiple drug co-administration giving the potential for many drug-drug interactions. Limited data is available regarding drug interactions of cardiovascular diseases in Egypt. This work studied potential drug-drug interactions of cardiovascular diseases in Egyptian patients with consideration to incidence, types, management, and prevention. Methods: A cross-sectional retrospective study was performed on outpatients with cardiovascular disorders in the Delta region of Egypt. About 4,100 prescriptions were analyzed for drug-drug interactions. Lexi-comp program was used as the screening tool. Results: The frequency of potential drug-drug interactions was 11% of which cardiovascular drugs represent 3 %. Major therapeutic classes of drug interactions with the cardiovascular drugs were analgesics, antiplatelets, anticoagulants, proton pump inhibitors, anti-gout, and Ginkgo herb. The risk for category X drug interaction requiring avoiding combinations was 39% and the risk for category D drug interaction requiring modifying drug was 61%. The main mechanisms for drug interaction were pharmacokinetics "metabolic inhibitions and P-gp inhibition" and pharmacodynamics interaction and the major reported toxicity was bleeding, nephrotoxicity, irregular heartbeats, visual disturbance, and myopathy. Conclusions: Preventive programs are required for the increased incidence of potential cardiovascular drug interaction in Egypt. Drug monitoring, minimizing risk factors, and increasing awareness of potential drug interaction in cardiovascular diseases are recommended in clinical practice in Egypt.

show abstract

Section: Resultsmentioning

confidence: 99%

Potential Cardiovascular Drug Interactions in Egypt: Incidence, Outcomes, Mechanism, and Management

Sobhy

Abdelmagged

Abdelaty

et al. 2021

Kafrelsheikh Veterinary Medical Journal

View full text Add to dashboard Cite

show abstract

Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens

Lusiki,

Blom,

Soko

et al. 2024

OMICS: A Journal of Integrative Biology

View full text Add to dashboard Cite

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma

Abdelkawy

Mahmoud

2023

Antibiotics

View full text Add to dashboard Cite

Background: Piperacillin (Pip)/tazobactam (Taz) is a broad-spectrum antimicrobial agent that has been commonly used in the intensive care unit for severe and life-threatening infections. Recent evidence suggests that therapeutic drug monitoring (TDM) for Pip could be beneficial in clinical practice to facilitate dose optimization and increase the odds of treatment success. The aim was to develop and validate a sensitive and simple high-performance liquid chromatography (HPLC) method for the simultaneous quantification of Pip and Taz in human plasma. Methods: Samples (0.3 mL) were deproteinized with acetonitrile. The supernatant was evaporated and then reconstituted and injected into the HPLC. The chromatographic analysis was carried out by using the C18 column and gradient elution with the acetonitrile:water mobile phase mixture with 0.1% trifluoracetic acid at a flow rate of 0.8 mL/min using a UV detector at 218 nm. Results: The method had acceptable linearity (r2 > 0.99) over the concentration ranges of 0.5–400 μg/mL and 1–100 μg/mL for Pip and Taz, respectively. The method demonstrated acceptable inter- and intra-day precision and accuracy within ±20% with adequate stability results. Conclusion: The developed method is sensitive and simple and utilizes simple sample preparation and elution steps, making it suitable and practical for Pip/Taz TDM.

show abstract

Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers

Cited by 3 publications

References 44 publications

Potential Cardiovascular Drug Interactions in Egypt: Incidence, Outcomes, Mechanism, and Management

Potential Cardiovascular Drug Interactions in Egypt: Incidence, Outcomes, Mechanism, and Management

Major Genetic Drivers of Statin Treatment Response in African Populations and Pharmacogenetics of Dyslipidemia Through a One Health Lens

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma

Contact Info

Product

Resources

About